My Medical CD Benchmark Research Coverage To Be Initiated By Investrend Research.

NEW YORK -- (Investrend Research Syndicate) My Medical CD Ltd. (OTC: MYMC) has enrolled in the unique shareholder empowerment platform administered by Investrend Communications, Inc., a provider of financial intelligence programs.

Benchmark research coverage will be initiated by Investrend Research analyst Oren Meytes, MBA. Investrend Research is located on the web at http://www.investrendresearch.com, and the analyst's qualifications are at http://www.investrend.com/articles/secondlevel.asp?level=238.

My Medical CD was founded in 2000 by a group of professionals that were acutely aware of the growing global need to consolidate individual medical histories onto a portable and updateable pocket size devise. The result of extensive research and meetings with government officials, experts in the medical field and first responders led to the development and creation of My Medical CD.

Utilizing state of the art technology and innovative software, the development team at MMCD created the first ever wallet sized CD that contains a wealth of detailed medical information as well as optional EKG's, x-rays, living wills, and other graphic and illustrative documents. The private company became a public entity in 2004.

The company's website is at http://www.mymedicalcd.com

An InvestorPower(TM) page has been created regarding the company at http://www.investrend.com/company/list.asp?sPathParam=yes.

Mr. Meytes is an experienced Senior Equity analyst with a focus on High-Tech. His coverage includes both public and private companies. As the Senior Analyst of Israel's biggest Venture Capital fund, he played a key part in the investment process in many successful technology companies, and had represented the fund in invested portfolio companies Boards of Directors. He is also a successful High-Tech entrepreneur and had co-founded a Software company which had been sold to Microsoft. He is a Magna Cum Laude UCLA graduate, and has an MSc. (Computer Science) and an MBA (Finance) from Tel Aviv Univ.

Investrend Research has been the leading independent equity research publishing and distribution program since 1996, with over 70 qualified professional analysts posting more than 800 reports. Anyone may enroll a company in the Investrend platforms. Enrollment fees for the Benchmark research platform are $19,800, which has been paid by the company. Analysts are paid in advance for their initial reports by Investrend Research to limit or eliminate pecuniary interests, and no one associated with the program may own or trade in the equities of companies under coverage.

Anyone interested in receiving alerts regarding My Medical CD research or webcasts should e-mail [e-mail] with "MYMC" in the subject line, or click on http://www.investrend.com/contact.asp.